Sunday, November 8, 2026

AUD/USD Jumps By 2% In The Last 21 Sessions

ViaNews Editorial Team

September 3, 2024

AUD/USD Jumps By 2% In The Last 21 Sessions

(VIANEWS) - AUD/USD (AUDUSD) has been up by 2.14% for the last 21 sessions. At 19:08 EST on Tuesday, 3 September, AUD/USD (AUDUSD) is $0.67.

Aud/usd plummets below 0.6750 as US dollar extends upside

The AUD/USD pair plunges below the crucial support of 0.6750 in Tuesday's European session.

AUD/USD's yearly highs and lows, it's 7.079% up from its 52-week low and 5.302% down from its 52-week high.

Previous days news about AUD/USD (AUDUSD)

  • Aud/usd trades with mild gains above 0.6750 ahead of Chinese pmi data. According to FXStreet on Sunday, 1 September, "The AUD/USD pair posts modest gains near 0.6770 after retreating from Friday's high of 0.6815 during the early Asian session on Monday. ", "However, the firmer US dollar after the US July's Personal Consumption Expenditures (PCE) Index might drag AUD/USD lower. "
  • Aud/usd price forecast: price is at a crossroads – is it correcting or reversing lower?. According to FXStreet on Monday, 2 September, "If AUD/USD can close back above 0.6800 it will signal a continuation of the uptrend back up to the 0.6824 high first, then possibly higher."

More news about AUD/USD (AUDUSD).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com